ArticleKidney medicine2026
A Novel Entity of Renal Toxicity After Combination Chemotherapy: An Onco-Nephrology Kidney Biopsy Teaching Case.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Concurrent Fabry disease, IgA nephropathy and undifferentiated connective tissue disease in a female with normal enzyme activity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal injury associated with combination cancer therapies represents a growing diagnostic challenge. Kidney biopsy enables early and appropriate detection of these cases, helping in accurate differential diagnosis and individualized management in these increasingly frequent and complex clinical settings. We report a tricky onco-nephrology teaching case involving a 65-year-old woman with recurrent high-grade Müllerian carcinoma who developed progressive kidney dysfunction, arterial hypertension, and new-onset subnephrotic range proteinuria during treatment with carboplatin, gemcitabine, and bevacizumab. Serologic tests were negative for autoimmune, viral, and hematologic causes. Kidney biopsy showed an advanced membranoproliferative pattern with eosinophilic and periodic acid-Schiff positive intracapillary deposits, diffuse endothelial injury, and unusual tubular myelin figures. Two weeks after kidney biopsy, the patient developed cutaneous purpura that shifted the diagnostic framework toward a systemic vasculopathy. This was supported by the ultrastructural evidence of polyclonal IgM-dominant organized intraluminal deposits and consistent with a drug-induced cryoglobulinemic glomerulonephritis superimposed on gemcitabine-induced chronic thrombotic microangiopathy with unexpected renal lipidosis. To our knowledge, this represents the first reported case of this specific renal injury profile in this clinical setting, underscoring the critical role of kidney biopsy in optimizing personalized care within the emerging field of onco-nephrology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.